The Scottish Medicines Consortium (SMC), Scotland’s health technology appraisal body, has made its first recommendations for medicines that have been awarded an innovation passport through the UK’s new Innovative Licensing and Access Pathway (ILAP).
The drugs, all to treat cancer, are Gilead Sciences, Inc.’s Trodelvy (sacituzumab govitecan), Amgen, Inc.’s Lumykras (sotorasib) and...








